Beck, Denise http://orcid.org/0000-0002-2730-6988
Winzenborg, Insa http://orcid.org/0000-0003-4015-7451
Liu, Mohan
Degner, Jacob http://orcid.org/0000-0003-4898-8575
Mostafa, Nael M. http://orcid.org/0000-0003-3065-768X
Noertersheuser, Peter http://orcid.org/0000-0002-3938-3040
Shebley, Mohamad http://orcid.org/0000-0002-0147-8933
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Documents that mention this clinical trial
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
https://doi.org/10.1007/s40262-021-01096-w
Funding for this research was provided by:
AbbVie
Article History
Accepted: 16 November 2021
First Online: 8 December 2021
Declarations
:
: This study was funded by AbbVie. AbbVie contributed to the study design, research, and interpretation of the data and the writing, review, and approval of the manuscript.
: DB, IW, ML, JD, NMM, PN, and MS are employees of AbbVie Inc. and may hold AbbVie stock and/or stock options.
: The studies reported herein were conducted in accordance with the International Council for Harmonisation guidelines, applicable regulations, guidelines governing clinical study conduct, and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating institutions.
: Informed consent was obtained from all individual participants included in the study.
: All individual participants signed an informed consent regarding the publishing of their data.
: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: ExternalRef removed.
: Not applicable.
: All authors contributed to the study design, analysis, and interpretation of the data. All authors participated in the drafting and revising of the manuscript.